G6PD and thalassemia: Genetic evaluations confirmed the absence of cystic fibrosis mutations and normal karyotypes; fragile X carrier screening revealed normal results, no mutations in coagulation genes (factors V, II, or MTHFR), and no thalassemia or glucose-6-phosphate dehydrogenase (G6PD) mutations.